Literature DB >> 9690569

The role and contribution of leukotrienes in asthma.

W Busse1.   

Abstract

LEARNING
OBJECTIVES: Reading this article will reinforce the reader's knowledge of the biochemistry and pharmacology of leukotrienes (LTs), including the enzymes and cells involved in their synthesis, the receptors that mediate their biologic effects, and the evidence that cysteinyl leukotrienes (CysLT) may play an important role in asthma. The 5-lipoxygenase inhibitors, 5-lipoxygenase-activating protein antagonists, and CysLT receptor antagonists are three classes of LTs modulators now in clinical use. The effects of these agents in clinical models of asthma induced by allergens, exercise, and aspirin and in multicenter asthma trials are reviewed. DATA SOURCES: Key papers published in peer-reviewed journals. STUDY SELECTION: Key papers published in peer-reviewed journals.
CONCLUSIONS: The pharmacology of these new medications and experience in clinical trials suggest that they may play a therapeutic role in the treatment of asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690569     DOI: 10.1016/S1081-1206(10)63106-7

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  5 in total

Review 1.  Pharmacokinetic profile of zafirlukast.

Authors:  P N Richard Dekhuijzen; Peter P Koopmans
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Role of LTB₄ in the pathogenesis of elastase-induced murine pulmonary emphysema.

Authors:  Y Michael Shim; Mikell Paige; Halim Hanna; Su H Kim; Marie D Burdick; Robert M Strieter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

4.  Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men.

Authors:  Renata Esposito; Giuseppe Spaziano; Domenico Giannattasio; Francesco Ferrigno; Angela Liparulo; Antonietta Rossi; Fiorentina Roviezzo; Maurizio Sessa; Maddalena Falciani; Liberato Berrino; Mario Polverino; Francesca Polverino; Bruno D'Agostino
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

5.  Tolerance and rebound with zafirlukast in patients with persistent asthma.

Authors:  David W Reid; Neil L Misso; Shashi Aggarwal; Philip J Thompson; David P Johns; E Haydn Walters
Journal:  J Negat Results Biomed       Date:  2008-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.